Use of TENS Unit in the Management of Endometriosis Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05348005|
Recruitment Status : Recruiting
First Posted : April 27, 2022
Last Update Posted : August 1, 2022
The purpose of this study is see if Transcutaneous Electrical Nerve Stimulator (TENS) units help decrease endometriosis flare pain. TENS units have a 510K and are intended for relief of pain associated with sore or aching muscles of the lower back, arms, or legs due to strain from exercise or normal household and work activities.
Participants will complete surveys, record pain, medication use and bleeding in an online diary during endometriosis flare ups for 3 months without using the TENS unit. After the first 3 month period of time, a TENS unit will be given to participants to wear and again, record pain, medication use and bleeding in the online diary during endometriosis flare ups for and additional 3 months while using the TENS unit.
|Condition or disease||Intervention/treatment||Phase|
|Endometriosis Pelvic Pain||Device: Ovira Transcutaneous Electrical Nerve Stimulation Unit||Not Applicable|
The investigators propose to conduct a cross-over clinical study to evaluate the effectiveness of TENS units on the management of endometriosis flare-related pain. Subjects will participate in a 3-month "baseline" period (no TENS unit use for endometriosis flares) and then cross-over to a 3-month "treatment" period (TENS unit use for endometriosis flares).
Potential subjects will be pre-screened in the Penn State Minimally Invasive GYN (MIGS) Surgery Clinic for pathologically diagnosed endometriosis and from the Penn State MIGS endometriosis database. Potential subjects will then be called to evaluate the remainder of the inclusion and exclusion criteria. If fulfilled, potential subjects will follow up at the enrollment visit (Visit 1) where consent is reviewed and signed. The baseline QOL and FSFI REDCap surveys will be completed at this visit. Subjects will be set up to receive automated links to complete diary entries and surveys directly in REDCap.
Prior to initiating TENS unit use for endometriosis flare-related pain, subjects will record daily entries into RedCap during episodes of endometriosis flares for 3 months. Each entry will record their VAS pain score as well as medication intake and bleeding profile.
Subjects will then be mailed the TENS unit at the 3 months mark into the study. Subjects will then complete entries with TENS use at their discretion for the following 3 months and record TENS unit use duration, frequency, and side effects in addition to the documentation of pain, medication and bleeding. At the end of the study, subjects will complete a QOL and FSFI survey.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||cross-over clinical study to evaluate the effectiveness of TENS units on the management of endometriosis flare-related pain. Subjects will participate in a 3-month "baseline" period (no TENS unit use for endometriosis flares) and then cross-over to a 3-month "treatment" period (TENS unit use for endometriosis flares).|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Cross-Over Study of the Use of Transcutaneous Electrical Nerve Stimulation Unit in the Management of Endometriosis Pain|
|Actual Study Start Date :||July 28, 2022|
|Estimated Primary Completion Date :||March 1, 2023|
|Estimated Study Completion Date :||December 31, 2023|
No Intervention: No TENS unit use
All subjects will start with 3 months of no TENS use and diary tracking
Active Comparator: TENS unit use
All subjects will then have 3 months of TENS use during episodes of endometriosis pain flare and diary tracking.
Device: Ovira Transcutaneous Electrical Nerve Stimulation Unit
TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
- Change in Average Daily VAS Pain Score [ Time Frame: Baseline Period (months 1-3) and Treatment Period (months 4-6) ]Average daily pain during endometriosis flares will be measured using a Visual Analog Scale (VAS), a horizontal line measuring pain from 0 (no pain) to 100 (worst pain), and compared between the baseline period (no TENS use) and treatment period (TENS use).
- Change in Quality of Life Score from baseline to end of study using the EHP30 questionnaire [ Time Frame: Baseline and 6 months ]Change in quality of life from baseline to end of study using the Endometriosis Health Profile (EHP30) questionnaire. Scores range from 0 (best health status) to 100 (worst health status).
- Change in Female Sexual Function Index Total Score using the FSFI questionnaire [ Time Frame: Baseline and 6 months ]Change in Female Sexual Function Index (FSFI) validated survey scores from baseline to end of study among participants who are currently partnered. FSFI total score ranges from 2.0 (poor) to 36.0 (best).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05348005
|Contact: Linda Li, MD||7175310003 ext email@example.com|
|United States, Pennsylvania|
|Penn State Health Milton S. Hershey Medical Center||Recruiting|
|Hershey, Pennsylvania, United States, 17033|
|Contact: Linda Li, MD 717-531-0003 ext 286762 firstname.lastname@example.org|
|Contact: Amyee McMonagle 7175314484|
|Sub-Investigator: Linda Li, MD|
|Principal Investigator: Kristin Riley, MD|
|Principal Investigator:||Kristin W Riley, MD||Penn State Health Hershey Medical Center|